Results 181 to 190 of about 585,966 (213)

The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy

Expert Review of Clinical Immunology, 2016
Lindsay E Nyhoff, Peggy L Kendall, Leslie J. Crofford   +2 more
exaly  

ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation

Modern Rheumatology, 2019
Christian Goess, Christopher M Harris
exaly  

Inhibitors of Bruton's tyrosine kinase

2018
LEE SEUNG, YAMAMOTO SHINGO
openaire   +5 more sources

Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X‐linked agammaglobulinaemia

EMBO Journal, 1997
Marko Hyvönen, Matti Saraste, M Saraste
exaly  

QSAR analysis of nicotinamidic compounds and design of potential Bruton’s tyrosine kinase (Btk) inhibitors

Journal of Biomolecular Structure and Dynamics, 2016
Elaine Fontes Ferreira da Cunha, Teodorico C Ramalho, Daniela Rodrigues Silva   +2 more
exaly  

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

European Journal of Medicinal Chemistry, 2018
Chengyuan Liang, Suresh Thareja, Xiaodong Ren   +2 more
exaly  

Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton’s tyrosine kinase inhibitors

Journal of Biomolecular Structure and Dynamics, 2018
Habeeb Shaik Mohideen
exaly  

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy

Cells, 2021
exaly  

Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis

Expert Opinion on Investigational Drugs, 2020
Martin S Weber
exaly  

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Blood, 2011
Samantha M Jaglowski, Amy J Johnson, Joseph M Flynn   +2 more
exaly